Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25888110 | 0.90 | HRH3 (0.40) | HRH3PIK3CD | |
| SCHEMBL25707430 | 0.90 | HRH3 (0.40) | HRH3PIK3CD | |
| SCHEMBL23695835 | 0.88 | HRH3 (0.42) | HRH3PIK3CDSIGMAR1MEN1KMT2A | |
| SCHEMBL25468942 | 0.88 | HRH3 (0.42) | HRH3PIK3CDSIGMAR1MEN1KMT2A | |
| SCHEMBL23560055 | 0.88 | HRH3 (0.42) | HRH3PIK3CDSIGMAR1MEN1KMT2A | |
| SCHEMBL25730402 | 0.85 | HRH3 (0.39) | HRH3PIK3CD | |
| SCHEMBL24854497 | 0.80 | HRH3 (0.42) | HRH3MEN1KMT2ACYP2D6 | |
| SCHEMBL14706853 | 0.80 | HRH3 (0.46) | HRH3PIK3CDMEN1KMT2ACYP2D6 | |
| SCHEMBL24854302 | 0.79 | KDM1A (0.34) | HRH3 | |
| SCHEMBL25110223 | 0.78 | HRH3 (0.43) | HRH3PIK3CDSIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885PIK3CD 321/4885SIGMAR1 3199/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885PIK3CD 321/4885SIGMAR1 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.